Literature DB >> 3190099

The geographic distribution of Lyme disease in the United States.

C A Ciesielski1, L E Markowitz, R Horsley, A W Hightower, H Russell, C V Broome.   

Abstract

In 1982, national surveillance for Lyme disease was established by the Centers for Disease Control to monitor trends and determine endemic geographic areas. Initially, the endemic areas corresponded to the known distribution of Ixodes dammini, a five-state area of the northeastern seaboard (New York, New Jersey, Connecticut, Rhode Island, and Massachusetts) and Wisconsin and Minnesota. Increasing numbers of cases have been reported outside these areas, however, 86% of the provisional 5731 cases reported to CDC were acquired in these seven states. The number of reported cases increased from 491 in 1982 to approximately 1500 per year in 1984-1986, making Lyme disease the most commonly reported tick-borne illness in the United States. The apparently widening distribution of Lyme disease indicates that physicians in all regions of the country should be familiar with its signs and symptoms. Investigations of the vector in areas endemic for Lyme disease where Ixodes ticks are not found are warranted.

Entities:  

Mesh:

Year:  1988        PMID: 3190099     DOI: 10.1111/j.1749-6632.1988.tb31862.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  11 in total

1.  Epidemiological study of a cohort of adult patients with Erythema migrans registered in Slovenia in 1993.

Authors:  F Strle; V Maraspin; S Furlan-Lotric; J Cimperman
Journal:  Eur J Epidemiol       Date:  1996-10       Impact factor: 8.082

2.  Detection of Borrelia burgdorferi using the polymerase chain reaction.

Authors:  D C Malloy; R K Nauman; H Paxton
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

3.  Temporal correlations between tick abundance and prevalence of ticks infected with Borrelia burgdorferi and increasing incidence of Lyme disease.

Authors:  K C Stafford; M L Cartter; L A Magnarelli; S H Ertel; P A Mshar
Journal:  J Clin Microbiol       Date:  1998-05       Impact factor: 5.948

4.  Comparison of indirect immunofluorescent-antibody assay, enzyme-linked immunosorbent assay, and Western immunoblot for the diagnosis of Lyme disease in dogs.

Authors:  J Lindenmayer; M Weber; J Bryant; E Marquez; A Onderdonk
Journal:  J Clin Microbiol       Date:  1990-01       Impact factor: 5.948

5.  A two year prospective study to compare culture and polymerase chain reaction amplification for the detection and diagnosis of Lyme borreliosis.

Authors:  M M Picken; R N Picken; D Han; Y Cheng; E Ruzic-Sabljic; J Cimperman; V Maraspin; S Lotric-Furlan; F Strle
Journal:  Mol Pathol       Date:  1997-08

6.  Recombinant OspA protects dogs against infection and disease caused by Borrelia burgdorferi.

Authors:  Y F Chang; M J Appel; R H Jacobson; S J Shin; P Harpending; R Straubinger; L A Patrican; H Mohammed; B A Summers
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

7.  Azithromycin and doxycycline for treatment of Borrelia culture-positive erythema migrans.

Authors:  F Strle; V Maraspin; S Lotric-Furlan; E Ruzić-Sabljić; J Cimperman
Journal:  Infection       Date:  1996 Jan-Feb       Impact factor: 3.553

8.  Dogs as sentinels for Lyme disease in Massachusetts.

Authors:  J M Lindenmayer; D Marshall; A B Onderdonk
Journal:  Am J Public Health       Date:  1991-11       Impact factor: 9.308

9.  Amplification of Borrelia burgdorferi DNA in skin biopsies from patients with Lyme disease.

Authors:  W Melchers; J Meis; P Rosa; E Claas; L Nohlmans; R Koopman; A Horrevorts; J Galama
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

10.  Azithromycin versus doxycycline for treatment of erythema migrans: clinical and microbiological findings.

Authors:  F Strle; V Preac-Mursic; J Cimperman; E Ruzic; V Maraspin; M Jereb
Journal:  Infection       Date:  1993 Mar-Apr       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.